The pharma giant says their drug abemaciclib garnered promising data in an interim analysis of MONARCH-3, a breast cancer trial that matched their drug with either of two aromatase inhibitors — letrozole or anastrozole — against only the aromatase inhibitor.
The full data will be rolled out later, with Eli Lilly limiting itself to the boast that their drug has the potential to be the best-in-class therapy in the likely three-way struggle to come.
Check out the full article here: Eli Lilly claims a lead role awaits its CDK 4/6 drug abemaciclib after PhIII success
Welcome to Clinical Research Trends, a new blog dedicated to providing breaking news on clinical trial recruitment, patient engagement, new technology and noteworthy trends. With this blog, we are working to provide clinical research organizations, sponsors and leading service providers with critical news and industry updates on a regular basis. If you want to learn more about the latest trends in clinical trial recruitment and drug development, you’ve come to the right place.